July 2013 to June 2014 | July 2014 to June 2015 | July 2015 to June 2016 | July 2016 to June 2017 | Ptrend 2014–2017 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Newly-arrived Asian-born MSMa | Other MSM | p | Newly arrived Asian born MSMa | Other MSM | p | Newly arrived Asian born MSMa | Other MSM | p | Newly arrived Asian born MSMa | Other MSM | p | Newly arrived Asian born MSMa | Other MSM | |
Individuals tested, n | 255b | 3,988c | 291b | 4422c | 402b | 5185c | 581b | 5608c | ||||||
HIV testsd, n | 409 | 6365 | 489 | 7212 | 745 | 8923 | 1138 | 10,462 | ||||||
Age in yrs., median (IQR)e | 26.3 (23.5–30.0) | 30.1 (25.3–37.8) | <.0001m | 26.7 (23.4–30.7) | 30.4 (25.6–38.0) | <.0001m | 26.6 (23.5–29.8) | 30.4 (25.7–38.2) | <.0001m | 26.7 (24.0–30.0) | 30.3 (25.6–37.5) | <.0001m | .79n | .07n |
Days since previous HIV test, median (IQR) | 133 (75–292) | 154 (86–316) | .017m | 116 (72–234) | 144 (83–296) | <.0001m | 106 (57–21) | 131 (78–270) | <.0001m | 114 (73–238) | 101 (61–189) | <.0001m | <.001n | <.001n |
PrEP use tests nf,g (%) | – | – | – | – | – | – | 7 (3.4%) | 79 (2.7%) | .55l | 39 (5.9%) | 721 (10.7%) | <.001l | .22n | <.001n |
PrEP n personsf,h (%) | – | – | – | – | – | – | 7 (3.5%) | 72 (2.7%) | .50l | 33 (6.8%) | 542 (11.1%) | <.001l | .19n | <.001n |
Tests with: | ||||||||||||||
Symptoms ng (%) | 71 (17.4%) | 1549 (24.3%) | .001l | 81 (16.6%) | 1676(23.2%) | .001l | 119 (16.0%) | 1976(22.2%) | <.001l | 195(17.1%) | 2059(19.7%) | .039l | .98n | <.001n |
Syphilisg n (%) | 3 (0.73%) | 78 (1.23%) | .38l | 6(1.23%) | 117 (1.62%) | .50l | 16 (2.15%) | 159 (1.78%) | .47l | 19 (1.67%) | 161 (1.54%) | .73l | .19n | .16n |
Pharyngeal gonorrhoeagn (%) | 6 (1.47%) | 106 (1.67%) | .76l | 7(1.43%) | 176 (2.44%) | .16l | 6 (0.81%) | 118 (1.32%) | .23l | 4 (0.35%) | 68 (0.65%) | .23l | .012n | <.001n |
Urethral gonorrhoeagn (%) | 8 (1.96%) | 145 (2.28%) | .67l | 4(0.82%) | 192 (2.66%) | .012l | 19 (2.55%) | 198 (2.22%) | .56l | 12 (1.05%) | 239 (2.28%) | .007l | .46n | .55n |
Urethral chlamydiagn (%) | 8 (1.96%) | 159 (2.50%) | .49l | 6 (1.23%) | 194 (2.69%) | .049l | 20 (2.75%) | 246 (2.75%) | .91l | 28 (2.46%) | 298 (2.85%) | .45l | .27n | .19n |
Anal gonorrhoeag n (%) | 11 (2.69%) | 180 (2.83%) | .97l | 17 (3.48%) | 283 (3.92%) | .62l | 41 (5.50%) | 510 (5.72%) | .81l | 61 (5.36%) | 535 (5.11%) | .72l | .017n | <.001n |
Anal chlamydiag n (%) | 31 (7.58%) | 308 (4.84%) | .014l | 37 (7.57%) | 315 (4.37%) | .001l | 67 (8.99%) | 628 (7.04%) | .047l | 89 (7.82%) | 740 (7.07%) | .35l | .83n | <.001n |
100% condom useg,in (%) | 226 (57.4%) | 3229 (53.4%) | .12l | 255 (56.3%) | 3405 (50.5%) | .016l | 354 (53.3%) | 3804 (47.0%) | .002l | 522 (51.9%) | 3537 (38.2%) | <.001l | .044n | <.001n |
10 or more partnersg,in (%) | 39 (9.54%) | 852 (13.4%) | .026l | 36 (7.36%) | 983 (13.6%) | <.001l | 48 (6.44%) | 1216 (13.6%) | <.001l | 110 (9.67%) | 1450 (13.9%) | <.001l | .54n | .43n |
Positive HIV testsj, n | 4 | 48 | 7 | 48 | 11 | 41 | 14 | 38 | ||||||
% testsg | 0.98% | 0.75% | .62l | 1.43% | 0.67% | .052l | 1.48% | 0.46% | <.001l | 1.23% | 0.36% | <.001l | 0.86n | <.001n |
% people testedh | 1.57% | 1.20% | .61l | 2.41% | 1.09% | .042l | 2.74% | 0.79% | <.001l | 2.41% | 0.68% | <.001l | .53n | .02n |
Incident HIVk, n | 3 | 33 | 5 | 39 | 7 | 33 | 9 | 21 | ||||||
% positivesi | 75.0% | 68.8% | .80l | 71.4% | 81.3% | .54l | 63.6% | 80.5% | .24l | 64.3% | 55.3% | .56l | .62n | .22n |
% testsf | 0.73% | 0.52% | .85l | 1.02% | 0.54% | .11l | 0.94% | 0.37% | <.001l | 0.79% | 0.20% | <.001l | .86n | <.001n |
% people testedg | 1.18% | 0.83% | .56l | 1.73% | 0.88% | .15l | 1.76% | 0.64% | .011l | 1.56% | 0.38% | <.001l | .76n | .001n |
(95%CI) | (0.38–3.60%) | (0.59–1.17%) | (0.72–4.09%) | (0.65–1.21%) | (0.84–3.65%) | (0.45–0.90%) | (0.81–2.98%) | (0.25–0.58%) |